The heavy selling by quant funds (Citadel, D.E. Shaw, Millennium) and active value manager Kahn Brothers signals growing institutional skepticism about OGN's near-term prospects. Monitor Q3 earnings for revenue weakness, especially in the women's health franchise, and watch for further insider selling. The 13F lag means some of this selling may have already been reflected in the stock price.
Executive Summary
A bearish institutional cluster emerged in Organon & Co. (OGN) during 2026-Q2, with 19 funds reducing positions (including Vanguard trimming 6.7M shares and Kahn Brothers cutting 2.9M shares) while only 5 funds added, led by Goldman Sachs and UBS. The divergence between active sellers (quant funds, Kahn Brothers) and passive buyers suggests deteriorating conviction among informed investors, reinforced by a confluence score of 22/100 indicating no insider open-market buying.
Key Financial Metrics
Institutional Positions
▲ Buyers (5)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Goldman Sachs | DOUBLED | +223.9% | $70.4M | $60.8M |
| UBS | ADD | +39.9% | $65.8M | $45.0M |
▼ Sellers (19)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Vanguard Portfolio Management | TRIM | -30.7% | $130.9M | $74.0M |
| Citadel | NEAR_EXIT | -82.8% | $12.0M | -$7.3M |
| D.E. Shaw | TRIM | -72.8% | $15.8M | -$6.1M |
| Kahn Brothers | TRIM | -51.8% | $33.2M | $3.0M |
| Millennium | TRIM | -49.2% | $40.6M | $6.0M |
Key Facts
- 19 institutions reduced holdings in Q2 2026 vs. 5 that increased, per 13F filings
- Vanguard Portfolio Management trimmed 6.7M shares (30.7% of its position)
- Kahn Brothers (active value) sold 2.9M shares, cutting 51.8% of its stake
- Citadel and D.E. Shaw nearly exited, reducing positions by 82.8% and 72.8% respectively
- Goldman Sachs doubled its position to $70.4M and UBS added to $65.8M, but these were predominantly passive/index-driven
- No insider open-market buying during the quarter (confluence score 22/100 divergent)
Financial Impact
19 sellers reduced positions with a net value change of $80.5M (including price appreciation), while 5 buyers added $108.3M in new holdings. Net share count was heavily skewed toward selling, with Vanguard's trim alone exceeding 6.7M shares.
Risk Factors
- Further institutional selling as more 13Fs are filed or as positions are unwound
- Revenue decline from generic competition to key products (e.g., Nexplanon)
- No insider buying to signal management confidence
- Potential for continued negative earnings revisions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-OGN-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | Institutional Cluster | $13.68 | awaiting T+60 | — | — |
Jul 31, 2026 12w ago | 8-K | $13.55 $13.74 | ▼ −1.40% | ▲ +1.05% | — |
Jul 17, 2026 14w ago | 8-K | $13.49 $13.77 | ▲ +2.08% | ▼ −2.76% | — |
Jun 17, 2026 18w ago | DEFM14A | $13.42 $13.64 | ▲ +1.64% | ▼ −1.51% | — |
Jun 11, 2026 19w ago | DEFA14A | $13.45 $13.78 | ▲ +2.45% | ▼ −1.94% | — |
Jun 1, 2026 21w ago | PREM14A | $13.37 $13.75 | ▲ +2.84% | ▲ +1.87% | — |
Apr 30, 2026 25w ago | DEFA14A | $13.25 $13.52 | ▲ +2.08% | ▼ −0.74% | — |
Apr 30, 2026 25w ago | 8-K | $13.25 $13.52 | ▼ −2.08% | ▲ +0.74% | — |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | — |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers